Laurus Labs Limited share price
NSE: LAURUSLABS · ISIN INE947Q01028
Key numbers
- Market cap
- ₹ 1,08,441 Cr
- Current price
- ₹ 2,007.00
- 52-week high / low
- ₹ 2,055 / 826
- Stock P/E
- 99.0
- Book value
- ₹ 98.2
- Dividend yield
- 0.12%
- ROCE
- 17.8%
- ROE
- 18.2%
- Debt to equity
- 0.48
- Sales growth (3 yrs)
- 3.8%
- Profit growth (3 yrs)
- 4.0%
- 1-year return
- 120.6%
About Laurus Labs Limited
Laurus Labs Limited, together with its subsidiaries, manufactures and sells medicines and active pharmaceutical ingredients (APIs) in India and internationally. The company offers Generics APIs and solid oral drug products for intermediates for anti-retroviral (ARV), anti-diabetic, cardiovascular, anti-asthma, ophthalmology, oncology, and gastroenterology. It also develops and manufactures animal-origin-free recombinant proteins and cell-culture media supplements and research and development services, including drug substance development, drug product development, and biologics development. In addition, the company offers non-human ingredients; rare disease therapeutics; and finished dosages. Laurus Labs Limited was incorporated in 2005 and is based in Hyderabad, India.
Quarterly results
Consolidated figures in ₹ crores
| Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|
| Sales | 1,720 | 1,570 | 1,778 | 1,812 | 2,026 |
| Operating profit | 421 | 382 | 480 | 512 | 638 |
| Net profit | 234 | 163 | 252 | 279 | 368 |
| EPS (₹) | 4.34 | 3.02 | 4.67 | 5.17 | 6.81 |
Investor presentation summary (2026-09-18)
AI summary of the presentation · tone: Positive · source document
Key numbers
- and FY28. Q1 CAPEX reached 19% of Revenue
- Continued strong Q1 performance ; ₹ 2,026 Cr Revenue with 29%
Guidance & outlook
- ₹ 3,000 Cr Cumulative CAPEX over FY27
- From FY22 to FY26, Laurus invested ₹ 4300 Cr building diversified portfolio across technologies and We are further
Growth & demand
- Demand, Scale and Future growth
- Healthy order book, internal pipeline and
Margins & costs
- EBITDA & Gross Profit Margins Revenue
- Gross margins expansion of over 3.3% pts to 62.7% on healthy
Capex & expansion
- Continuing CAPEX in large-scale API & fermentation capacity
- Demand led capacity creation & Invest in enviable technologies
Peers in Drug Manufacturers - Specialty & Generic
Data for information only, not investment advice. Prices end of day.